Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H2 2017

  • ID: 4418955
  • Drug Pipelines
  • 63 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • ARMO Biosciences Inc
  • Bristol-Myers Squibb Co
  • GlaxoSmithKline Plc
  • Incyte Corp
  • Merck & Co Inc
  • Prima BioMed Ltd
  • MORE
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H2 2017

Summary

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Lymphocyte-activation gene 3 or LAG-3 is a protein encoded by the LAG3 gene. It is involved in the maturation and activation of dendritic cells and lymphocyte activation. It binds to HLA class-II antigens.

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) pipeline Target constitutes close to 22 molecules. Out of which approximately 22 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 8, 8 and 4 respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular and Infectious Disease which include indications Solid Tumor, Non-Small Cell Lung Cancer, Advanced Malignancy, Autoimmune Disorders, Lymphoma, Melanoma, Bladder Cancer, Blood Cancer, Cardiovascular Disease, Cervical Cancer, Chronic Inflammation, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Gastric Cancer, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Kidney Cancer (Renal Cell Cancer), Non-Hodgkin Lymphoma, Ovarian Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Recurrent Glioblastoma Multiforme (GBM), Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma and Renal Cell Carcinoma.

The latest report Lymphocyte Activation Gene 3 Protein - Pipeline Review, H2 2017, outlays comprehensive information on the Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)
  • The report reviews Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ARMO Biosciences Inc
  • Bristol-Myers Squibb Co
  • GlaxoSmithKline Plc
  • Incyte Corp
  • Merck & Co Inc
  • Prima BioMed Ltd
  • MORE
Introduction

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Overview

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Companies Involved in Therapeutics Development

ARMO Biosciences Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Crescendo Biologics Ltd

Enumeral Biomedical Holdings Inc

GlaxoSmithKline Plc

Icell Kealex Therapeutics

Incyte Corp

MacroGenics Inc

Merck & Co Inc

Novartis AG

Prima BioMed Ltd

Regeneron Pharmaceuticals Inc

Sutro Biopharma Inc

Tesaro Inc

Xencor Inc

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Drug Profiles

AM-0003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-754111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Inhibit LAG3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Target PD-1 and LAG-3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENUM-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IKT-203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMP-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMP-731 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMP-761 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LAG-525 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGD-013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-4280 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit LAG-3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit LAG3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit PD-1 and LAG-3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Target PD-1 and LAG-3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Replace CD223 for Cardiovascular Disease and Chronic Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-2810 + REGN-3767 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-3767 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TSR-033 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XmAb-22841 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Dormant Products

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Product Development Milestones

Featured News & Press Releases

Sep 08, 2017: Prima Secures Japanese Patent Grant for IMP731 Antibody

Sep 05, 2017: MacroGenics Provides Update on its DART candidate MGD013

Jul 16, 2017: Prima BioMed Announces Second Milestone Payment for IMP701 Program

Jun 03, 2017: Anti-LAG-3 (BMS-986016) in Combination with Opdivo (nivolumab) Showed Activity in Patients with Melanoma Who Were Relapsed or Refractory to Anti-PD-1/PD-L1 Therapy

May 01, 2017: TESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to the U.S. FDA

Jan 03, 2017: Prima Announces New Product Candidate IMP761 - A LAG-3 Agonist Antibody

Aug 25, 2016: European Patent Grants for IMP731 Antibody

Apr 19, 2016: MacroGenics Presents Data from MGD013 Preclinical Program at AACR Annual Meeting

Feb 08, 2016: Crescendo Biologics Presents Key Oncology Data on Humabody Drug Conjugates

Jan 27, 2016: US Patent Grants for IMP731 Antibody

Aug 14, 2015: Prima Biomed Announces Commencement of Milestones for IMP701 Program

May 27, 2015: Crescendo Biologics Expands ADC Programmes with Innovate UK Funding Award

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Therapy Areas, H2

Number of Products under Development by Indications, H2

Number of Products under Development by Companies, H2

Products under Development by Companies, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Pipeline by ARMO Biosciences Inc, H2

Pipeline by Boehringer Ingelheim GmbH, H2

Pipeline by Bristol-Myers Squibb Co, H2

Pipeline by Crescendo Biologics Ltd, H2

Pipeline by Enumeral Biomedical Holdings Inc, H2

Pipeline by GlaxoSmithKline Plc, H2

Pipeline by Icell Kealex Therapeutics, H2

Pipeline by Incyte Corp, H2

Pipeline by MacroGenics Inc, H2

Pipeline by Merck & Co Inc, H2

Pipeline by Novartis AG, H2

Pipeline by Prima BioMed Ltd, H2

Pipeline by Regeneron Pharmaceuticals Inc, H2

Pipeline by Sutro Biopharma Inc, H2

Pipeline by Tesaro Inc, H2

Pipeline by Xencor Inc, H2

Dormant Projects, H2

List of Figures

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Therapy Areas, H2

Number of Products under Development by Top 10 Indications, H2

Number of Products by Mechanism of Actions, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • ARMO Biosciences Inc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Crescendo Biologics Ltd
  • Enumeral Biomedical Holdings Inc
  • GlaxoSmithKline Plc
  • Icell Kealex Therapeutics
  • Incyte Corp
  • MacroGenics Inc
  • Merck & Co Inc
  • Novartis AG
  • Prima BioMed Ltd
  • Regeneron Pharmaceuticals Inc
  • Sutro Biopharma Inc
  • Tesaro Inc
  • Xencor Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll